Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 20/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542095 | 0.88 | GRM5 (0.67) | GRM5PGRKCNH2 | |
| SCHEMBL16635741 | 0.88 | GRM5 (0.69) | GRM5 | |
| SCHEMBL4539727 | 0.87 | GRM5 (0.67) | GRM5PGRKCNH2 | |
| SCHEMBL16636195 | 0.85 | GRM5 (0.67) | GRM5PGRKCNH2 | |
| SCHEMBL13642538 | 0.82 | GRM5 (0.70) | GRM5PGRKCNH2 | |
| SCHEMBL5022074 | 0.82 | GRM5 (0.70) | GRM5PGRKCNH2 | |
| SCHEMBL16635501 | 0.81 | GRM5 (0.66) | GRM5PGRKCNH2 | |
| SCHEMBL16635494 | 0.81 | GRM5 (0.64) | GRM5 | |
| SCHEMBL4539794 | 0.80 | GRM5 (0.67) | GRM5 | |
| SCHEMBL4537089 | 0.80 | GRM5 (1.00) | GRM5PGRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688669-B2 | Oxazolidinones as modulators of mGluR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| EP-3055306-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | Bristol-Myers Squibb Company (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054103-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885PGR 1709/4885KCNH2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.